CClinicalTrials.gg
Status unknownNCT01002001Updated Oct 27, 2009

Sleep Disorders Pre and Post Liver Transplantation

An observational study in Liver Cirrhosis, sponsored by University Health Network, Toronto. Status unknown at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2009-10-27.

Sponsored by University Health Network, Toronto · Observational

The sponsor has not verified this record recently (last verified Oct 2009), so the status shown — last known as Enrolling by invitation — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Sleep disturbance and sexual dysfunction are common complaints of patients with cirrhosis . The term sleep disturbance describes insomnia, poor quality sleep, circadian rhythm disorders and obstructive sleep apnea and is associated with reduced health-related quality of life (HRQoL) score indices. Sleep and sexual disorders have only been formally evaluated in small studies in these patients and to date, no studies have objectively assessed these patients. In addition, no studies have been performed in these patients after liver transplantation. The investigators' hypothesis is that sleep and sexual disturbance is commonly seen in patients with advanced cirrhosis and improves after liver transplantation. However, despite this, HRQoL remain impaired because of residual sleep disturbance.This study will be unique in providing cross-sectional follow-up of patients with cirrhosis at baseline and after liver transplantation (> 6 months).

02

Conditions studied

  • Liver Cirrhosis

Browse trials for

03

In context

Liver Cirrhosis

1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.

This study's planned enrollment of 200 is above the median of 151 across 587 observational studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,411 studies on the registry; 292 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients attending the pre and post-transplantation liver clinics

Inclusion criteria

  • Liver cirrhosis
  • Comprehend and read English
  • On liver transplantation list or post-liver transplantation

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking
  • \< 18 years and > 85 yrs
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
06

What researchers measure

Primary outcomes

  1. Sleep disturbances in patients with advanced cirrhosis

    Time frame: 18 months

07

Study locations

1 site
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 27, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01002001
Lead sponsor
University Health Network, Toronto
First posted
Oct 27, 2009
Start date
Oct 2009
Primary completion
Dec 2010 (estimated)
Completion
Dec 2010 (estimated)
Last update
Oct 27, 2009

Study contacts

George Therapondos, MD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion